|Fastest Growing Market:||Europe|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The cell signaling market was valued at approximately USD 3,455 million in 2020, and it is expected to reach USD 4,945 million by 2026, registering a CAGR of nearly 6.2% during the forecast period, 2021-2026.
The COVID-19 pandemic is likely to have a profound impact on the market studied. A new study published in the journal News Medical, "SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells" in October 2020 stated that vascular cells in the lung tissue begin to secrete signaling growth factors when exposed to just the spike protein of severe acute respiratory syndrome coronavirus without the rest of the viral components. As this signaling mechanism is potentially linked to worse outcomes in this situation, these findings could indicate new targets for the development of therapeutic agents. Thus, the high utility of cell signaling models for research about COVID-19 and respiratory diseases is expected to offer significant growth opportunities to the market.
The major factors for the growth of the cell signaling market include the rising incidence of chronic diseases, increased funding for cell-based research, and technological advancements in cell-based research instruments. There is rising funding for cell-based research across the world.
For instance, according to the data available on the portal for the National Institutes of Health (NIH), an estimated USD 1,626 million was granted for stem cell research in the fiscal year 2019. In contrast, the actual fund grants for stem cell research in the fiscal year 2018, amounted to USD 1,748 million.
Similar increments in funding grants were observed for research in the areas of embryonic stem cell and induced pluripotent stem cell. Similar positive trends in the increment of fund grants have been observed in the European Union for cell-based research. Consequently, the increasing participation of the government in the development of cell-based research, in the form of incremental funding, is expected to drive the growth of the market studied. Other factors contributing to the growth of the market studied include the increasing incidence of chronic diseases and technological advancements in cell-based research instruments.
However, the high cost of cell signaling systems and ethical issues related to embryonic stem cell signaling research are likely to hinder the market growth.
Scope of the Report
As per the scope of this report, cell signaling refers to the communication processes that trigger cellular activities and coordinate cellular actions. Irregularities and errors in cell signaling are responsible for diseases, like cancer, and many other autoimmune diseases, like diabetes. The cell signaling market is segmented by signaling type (endocrine signaling, paracrine signaling, autocrine signaling, synaptic signaling, and other signaling types), product (instruments and consumables), technology (flow cytometry, mass spectrometry, western blotting, ELISA, and other technologies), pathway (AKT signaling pathway, AMPK signaling pathway, ErbB/HER signaling pathway, and other signaling pathways), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.
|By Signaling Type|
|Other Signaling Types|
|AKT Signaling Pathway|
|AMPK Signaling Pathway|
|ErbB/HER Signaling Pathway|
|Other Signaling Pathways|
Key Market Trends
The AKT Signaling Pathway Segment is Expected to Register Good Growth Over the Forecast Period
The AKT signaling pathway, also known as the survival pathway, is responsible for the increased proliferation, loss of apoptosis signaling, and cell growth. The AKT signaling pathway is the most commonly dysregulated pathway in the most prevalent forms of cancer. A number of drugs have been designed based on the rationale that inhibition of AKT pathway, which could help in achieving therapeutic results. A number of drugs based on AKT signaling are currently in various stages of clinical trials.
In the treatment of advanced-stage COVID-19 patients, AKT is found as a potential therapeutic target. Its inhibition will potentially suppress the cytokine storm, fibroproliferation, pathological inflammation, and platelet activation associated with COVID-19. It also promotes resolution and prevents scarring in injured lungs. As per the study published "AKT a viable option to treat advanced-stage COVID-19 patients" in 2020, pharmacological inhibition of AKT has also been reported to inhibit angiotensin-converting enzyme 2 (ACE2) expression, a receptor for the virus entry into the lung cells, and targeting AKT for COVID-19 looks like a viable option.
AKT inhibitors can be classified into four categories. The first category consists of competitive inhibitors of the ATP binding site on the kinase domain. The second category is allosteric inhibitors of the AKT kinase domain. Other similar categories of the drug exist, which are based on the regulation of AKT pathway. Overall, the market for the AKT signaling pathway has the largest share due to the comprehensive list of pipeline drugs, which are based on the regulation of AKT signaling.
Over the forecast period, this market is expected to grow, as commercial diagnostic tests are expected to emerge based on down-regulation of the AKT pathway.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Market Over the Forecast Period
North America is found to hold a major share of the cell signaling market and is expected to show a similar trend over the forecast period, without significant fluctuations. The cell signaling market is expected to witness numerous growth opportunities during the pandemic, with cell signaling pathways being utilized as experimental virology platforms to study the immune responses and infectivity of SARS-CoV-2. Most of the major players have been involved in R&D activities regarding cell signaling pathways. The mortality in most of the COVID-19 patients is due to the presence of a cytokine storm, which is induced by the virus. The excessive production of these proinflammatory cytokines leads to acute respiratory distress syndrome aggravation and widespread tissue damage, which results in multi-organ failure and death. Thus, targeting cell signaling pathways such as cytokines during the management of COVID-19 may lead to the reduction of the mortality rate and improved outcomes. This is likely to have a positive impact on the market studied.
In the United States, for the fiscal year 2018, USD 520 million was granted by the federal government for the National Cancer Institute (NCI) budget for breast cancer research, USD 212 million for colorectal cancer research, and USD 241 million for leukemia. Additionally, the estimates available on the National Institute of Health Portal for stem cell-based research indicate a cumulative funding budget of more than USD 3 billion for research in various fields of stem cell applications. The need for cell signaling in cancer research plays a vital role in the progressive growth of the cell signaling market in the United States. The growing funding in cancer research and stem cell research are directly causing an increase in cell signaling research, particularly in the United States. The increasing trend of increment in research funding is expected to lead to the growth of the market studied in the United States.
To understand geography trends, Download Sample Report
The market studied is a moderately consolidated market owing to the presence of small and large market players. Some of the market players are Beckman Coulter Inc. (Danaher), Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Cell Signaling Technology Inc., Merck KGaA, PerkinElmer Inc., Promega Corporation, Qiagen NV, and Thermo Fischer Scientific Inc.
In 2020, Beckman Coulter Life Sciences launched the DxFLEX, Europe’s first CE-IVD, 13-color clinical flow cytometry system. The sensitivity and resolution of the DxFLEX expand laboratory testing capabilities, especially those focusing on user-defined assays.
In 2020, Thermo Scientific launched High-Resolution Mass Spectrometer. The new High-Resolution Mass Spectrometer redefines productivity in characterization, identification, and quantitation in unknown small molecule and peptide mapping applications.
Table of Contents
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Chronic Diseases
4.2.2 Increased Funding for Cell-based Research
4.2.3 Technological Advancements in Cell-based Research Instruments
4.3 Market Restraints
4.3.1 High Cost of Cell Signaling Systems
4.3.2 Ethical Issues Related to Embryonic Stem Cell Signaling Research
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Signaling Type
5.1.1 Endocrine Signaling
5.1.2 Paracrine Signaling
5.1.3 Autocrine Signaling
5.1.4 Synaptic Signaling
5.1.5 Other Signaling Types
5.2 By Product
5.3 By Technology
5.3.1 Flow Cytometry
5.3.2 Mass Spectrometry
5.3.3 Western Blotting
5.3.5 Other Technologies
5.4 By Pathway
5.4.1 AKT Signaling Pathway
5.4.2 AMPK Signaling Pathway
5.4.3 ErbB/HER Signaling Pathway
5.4.4 Other Signaling Pathways
5.5.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East and Africa
5.5.5 South America
220.127.116.11 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 Bio-Techne Corporation
6.1.4 Cell Signaling Technology Inc.
6.1.5 Danaher Corporation (Beckman Coulter Inc.)
6.1.6 Merck KGaA
6.1.7 PerkinElmer Inc.
6.1.8 Promega Corporation
6.1.9 Qiagen NV
6.1.10 Thermo Fischer Scientific Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Cell Signaling Market market is studied from 2018 - 2026.
What is the growth rate of Global Cell Signaling Market?
The Global Cell Signaling Market is growing at a CAGR of 6.2% over the next 5 years.
What is Global Cell Signaling Market size in 2018?
The Global Cell Signaling Market is valued at 3455 Million USD in 2018.
What is Global Cell Signaling Market size in 2026?
The Global Cell Signaling Market is valued at 4945 Million USD in 2026.
Which region has highest growth rate in Global Cell Signaling Market?
Europe is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Cell Signaling Market?
North America holds highest share in 2020.
Who are the key players in Global Cell Signaling Market?
Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., PerkinElmer Inc., Becton, Dickinson and Company, Danaher Corporation are the major companies operating in Global Cell Signaling Market.